8.4 Amniotic Fluid Embolism (Anaphylactoid Syndrome of Pregnancy)
Key Takeaways
- Amniotic Fluid Embolism (AFE)—more accurately designated the Anaphylactoid Syndrome of Pregnancy—is a rare (1.5 to 6 per 100,000 deliveries) but catastrophic obstetric emergency characterized by a severe, immune-mediated, systemic inflammatory and anaphylactoid cascade triggered by the entry of fetal antigens and amniotic fluid into the maternal venous circulation.
- AFE classically manifests as a devastating clinical triad: (1) Acute maternal hypoxemic respiratory failure and pulmonary hypertension, (2) Sudden cardiovascular collapse and cardiogenic shock, and (3) Severe consumptive coagulopathy and Disseminated Intravascular Coagulation (DIC), typically presenting during active labor, immediately following membrane rupture, or within 30 minutes postpartum.
- The pathophysiological progression of AFE is biphasic: Phase 1 features acute, intense pulmonary arterial vasospasm, acute right ventricular failure (acute cor pulmonale), severe ventilation-perfusion mismatch, hypoxia, and cardiogenic shock; Phase 2 features left ventricular failure, secondary cardiogenic pulmonary edema, and sudden profound consumptive coagulopathy with massive hypofibrinogenemia.
- The modern pharmacologic resuscitation protocol for AFE is the evidence-based A-OK Protocol: Atropine (0.8–1.0 mg IV) to counteract vagal-mediated bradycardia and pulmonary vasospasm, Ondansetron (8 mg IV) to block serotonin (5-HT3) receptors and blunt pulmonary vasoconstriction, and Ketorolac (30 mg IV) to inhibit cyclooxygenase (COX) and halt thromboxane synthesis and platelet microthrombi aggregation.
- Critical cardiopulmonary resuscitation modifications in maternal cardiac arrest include continuous manual Left Uterine Displacement (LUD) to relieve aortocaval compression, chest compressions placed slightly higher on the sternum, aggressive Massive Transfusion Protocol (MTP) with high-ratio blood products and cryoprecipitate (maintaining fibrinogen >200 mg/dL), and executing a Perimortem Cesarean Delivery (Resuscitative Hysterotomy) initiated within 4 minutes of arrest and delivered by 5 minutes if maternal return of spontaneous circulation (ROSC) is not achieved.
Pathophysiology & The Anaphylactoid Cascade
Historically, Amniotic Fluid Embolism (AFE) was conceptualized as a purely mechanical obstruction of the maternal pulmonary arterial tree by fetal particulate matter (squamous cells, lanugo, meconium, mucin). Modern scientific, immunological, and hemodynamic investigations have completely redefined this paradigm: AFE is now recognized as Anaphylactoid Syndrome of Pregnancy, an overwhelming, immune-mediated systemic inflammatory and anaphylactoid reaction triggered when fetal antigens, trophoblastic debris, and pro-inflammatory components of amniotic fluid enter the maternal venous circulation through disrupted endocervical, uterine, or placental vascular beds.
The clinical syndrome unfolds in a classic biphasic pathophysiological cascade:
+---------------------------------------------------------------------------------------------------+
| BIPHASIC PATHOPHYSIOLOGICAL CASCADE OF AFE |
+---------------------------------------------------------------------------------------------------+
│
[ Entry of Amniotic Fluid / Fetal Antigens into Maternal Venous Circulation ]
(Via endocervical veins, uterine trauma site, or placental separation plane)
│
▼
[ ACTIVATION OF MASSIVE INFLAMMATORY / IMMUNE CASCADE ]
• Massive degranulation of mast cells
• Explosive release of Endothelin, Serotonin (5-HT), Thromboxane A2, Leukotrienes
• Complement cascade activation (C3a, C5a anaphylatoxins)
│
┌────────────────────────────────┴────────────────────────────────┐
▼ ▼
[ PHASE 1: ACUTE PULMONARY VASOSPASM ] [ PHASE 2: LEFT HEART FAILURE & DIC ]
• Severe pulmonary arterial vasoconstriction • Secondary myocardial depression (LVEF drops)
• Acute, massive PULMONARY HYPERTENSION • Acute hydrostatic cardiogenic pulmonary edema
• Acute RIGHT VENTRICULAR FAILURE (Cor Pulmonale) • Massive consumption of clotting factors
• Severe right-to-left intra-cardiac shunting • Severe CONSUMPTIVE COAGULOPATHY (DIC)
• Profound ventilation-perfusion (V/Q) mismatch • Critical HYPOFIBRINOGENEMIA (<100-150 mg/dL)
• Sudden Severe Hypoxia, Cyanosis, Shock • Catastrophic maternal hemorrhage & atony
│ │
└────────────────────────────────┬────────────────────────────────┘
│
▼
[ MULTISYSTEM ORGAN FAILURE / CARDIOPULMONARY ARREST ]
Clinical Diagnostic Criteria (SMFM / AFE Foundation)
AFE is a clinical diagnosis of exclusion. The Society for Maternal-Fetal Medicine (SMFM) and the Amniotic Fluid Embolism Foundation have established standardized diagnostic criteria for research and clinical surveillance:
- Sudden onset of Cardiorespiratory Arrest OR Hypotension (Systolic BP <90 mmHg) with Hypoxemia (SpO2 <90% or PaO2 <60 mmHg).
- Documentation of Overt Coagulopathy (DIC): Consumptive coagulopathy meeting clinical DIC criteria (prolonged PT/INR, prolonged aPTT, platelets <100,000/μL, or fibrinogen <200 mg/dL) developing early in the course.
- Onset during Labor, Cesarean Delivery, Dilation and Evacuation, or within 30 Minutes Postpartum.
- Absence of Other Explanatory Medical Conditions (e.g., severe sepsis, massive pulmonary thromboembolism, myocardial infarction, acute anaphylaxis, or local anesthetic systemic toxicity).
Clinical Presentation & Premonitory Warning Signs
The onset of AFE is abrupt, violent, and unpredictable. In over 80% to 90% of cases, patients exhibit distinct premonitory aura signs seconds to minutes prior to cardiorespiratory collapse:
- Neurological & Psychological Symptoms: Sudden acute sense of impending doom, intense agitation, profound anxiety, sudden paresthesias, dizziness, or sudden generalized tonic-clonic seizure activity.
- Respiratory Warning Signs: Sudden gasp for air, severe dyspnea, choking sensation, coughing, tachypnea, and rapidly progressive cyanosis.
- Fetal Indicators: Immediate, severe, prolonged fetal heart rate deceleration or terminal bradycardia (<70 bpm) reflecting acute maternal hypoxemia and uterine hypoperfusion.
- Hemodynamic Collapse: Precipitous drop in blood pressure, pulseless electrical activity (PEA) or ventricular fibrillation, acute loss of consciousness, and cardiac arrest.
- Catastrophic Hemorrhage & DIC: Within 10 to 30 minutes of the initial arrest, widespread intractable bleeding erupts from the uterus (torrential atony), IV puncture sites, surgical incisions, bladder catheter, and mucous membranes. Laboratory evaluation reveals profound hypofibrinogenemia (often <50–100 mg/dL), severe thrombocytopenia, and markedly elevated D-dimer and fibrin degradation products.
Targeted Pharmacotherapy: The A-OK Protocol
In recent years, the clinical management of AFE has been transformed by the targeted A-OK pharmacologic regimen, developed by Clark, Pacheco, and colleagues to block the specific neuro-humoral and inflammatory mediators that drive the acute fatal cascade:
+---------------------------------------------------------------------------------------------------+
| THE A-OK PHARMACOLOGIC REGIMEN FOR AFE |
+---------------------------------------------------------------------------------------------------+
[ A ] - ATROPINE (0.8 to 1.0 mg IV Push)
• Blocks parasympathetic muscarinic receptors.
• Counteracts vagally mediated profound bradycardia.
• Blunts pulmonary arteriolar and coronary artery vasospasm triggered by vagal reflex.
│
▼
[ O ] - ONDANSETRON (8 mg IV Push)
• Potent Serotonin 5-HT3 receptor antagonist.
• Blocks massive serotonin release from lysed platelets and activated mast cells.
• Prevents severe pulmonary arterial vasoconstriction and suppresses the vagal
Bezold-Jarisch cardiovascular inhibitory reflex.
│
▼
[ K ] - KETOROLAC (30 mg IV Push)
• Potent non-steroidal anti-inflammatory drug (NSAID); blocks Cyclooxygenase (COX).
• Halts the rapid biosynthesis of Thromboxane A2 and Prostaglandin F2α.
• Prevents platelet microthrombi aggregation and microvascular thrombosis in the
pulmonary capillary bed.
*TIMING: Administer all three medications in rapid succession immediately upon clinical suspicion of AFE!*
Advanced Resuscitation & Critical Care Management
+---------------------------------------------------------------------------------------------------+
| STEPWISE CRITICAL CARE ALGORITHM FOR AFE COLLAPSE |
+---------------------------------------------------------------------------------------------------+
[ STEP 1 ] - ACTIVATE CODE BLUE / CODE OB & ADVANCED LIFE SUPPORT
• Call immediate cardiac arrest code; assemble Multi-disciplinary Critical Care Team
(OB, Anesthesia, MFM, Intensivist, Trauma/Surgical ICU, Neonatology).
│
▼
[ STEP 2 ] - IMMEDIATE HIGH-QUALITY CPR MODIFICATIONS IN PREGNANCY
• Manual Left Uterine Displacement (LUD): Continuous leftward displacement of the
gravid uterus off the inferior vena cava (IVC) and aorta using a two-handed technique.
• Chest Compressions: Position hands slightly higher on the sternum (above the center
of the chest) to compensate for diaphragmatic elevation from the gravid uterus.
• Airway & 100% Oxygenation: Immediate endotracheal intubation (smaller ETT size, e.g.,
6.0-7.0 mm); prioritize high-flow ventilation; minimize excessive PEEP (which impedes RV venous return).
│
▼
[ STEP 3 ] - TARGETED PHARMACOLOGIC & HEMODYNAMIC RESUSCITATION
• Administer A-OK Protocol: Atropine (1 mg) + Ondansetron (8 mg) + Ketorolac (30 mg) IV.
• Hemodynamic Inotropes & Vasopressors: First-line NOREPINEPHRINE to maintain systemic
vascular resistance; add EPINEPHRINE or VASOPRESSIN as needed.
• Inodilator support: DOBUTAMINE or MILRINONE to support failing Right Ventricle.
• Strict Fluid Restriction: AVOID excessive crystalloid boluses! Over-hydration rapidly
induces acute right ventricular fluid overload, leftward septal shift, and fatal pulmonary edema.
│
▼
[ STEP 4 ] - AGGRESSIVE DIC MANAGEMENT & MASSIVE TRANSFUSION PROTOCOL (MTP)
• Activate Level-1 MTP immediately (PRBCs, FFP, Platelets in 1:1:1 ratio).
• Aggressive Cryoprecipitate: Administer 10 to 20 units of cryoprecipitate or fibrinogen
concentrate to maintain serum Fibrinogen >200 mg/dL.
• Tranexamic Acid (TXA): 1 g IV over 10 minutes (administer within 3 hours of event).
• Place indwelling Bakri intrauterine balloon and administer systemic uterotonics for atony.
│
▼
[ STEP 5 ] - RESUSCITATIVE HYSTEROTOMY / PERIMORTEM CESAREAN DELIVERY
• If maternal cardiac arrest occurs in a pregnant patient ≥20-24 weeks gestation:
- IF NO ROSC WITHIN 4 MINUTES: INITIATE RESUSCITATIVE HYSTEROTOMY AT BEDSIDE.
- DELIVER THE FETUS BY 5 MINUTES FROM CARDIAC ARREST ONSET.
• Primary goal is MATERNAL RESUSCITATION: Relieves 100% of aortocaval compression, reduces
pelvic vascular steal, and increases maternal cardiac venous return by >30-40%.
A G3P2 in active labor at 39 weeks of gestation suddenly sits up in bed, clutches her chest, states 'I feel like I'm going to die,' and becomes severely dyspneic and cyanotic. Her blood pressure drops to 60/30 mmHg, pulse oximetry displays 74% on room air, and the fetal monitor displays terminal bradycardia of 60 bpm. Within 15 minutes, the patient begins oozing frank blood from her peripheral IV sites and Foley catheter. What is the underlying pathophysiology of this condition?
Which specific pharmacologic agents comprise the evidence-based A-OK protocol utilized in the emergency management of Amniotic Fluid Embolism (AFE)?
During maternal cardiopulmonary resuscitation (CPR) for a 36-week pregnant patient in pulseless cardiac arrest from suspected AFE, what critical modification must the resuscitation team execute simultaneously with chest compressions?
A patient at 37 weeks of gestation experiences a cardiac arrest from suspected Amniotic Fluid Embolism. High-quality CPR, Left Uterine Displacement, and advanced airway management have been ongoing for 4 minutes with no return of spontaneous circulation (ROSC). What is the mandatory next intervention?